The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Recruiting · NCT05802407 · Interventional (participants receive a specific treatment) · Lead sponsor: Peking Union Medical College Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Later-line therapy
What this trial is about
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection);
- both sexes, age ≥18 years old;
- ECOG performance status score ≤2;
- the expected survival time was ≥3 months.
Exclusion criteria
- a known diagnosis of pancreatic cancer other than ductal adenocarcinoma;
- treated with any systemic antitumor treatment before first-line chemotherapy onset;
- died or lost to follow-up within one month after the initiation of adjuvant chemotherpay;
- combined with other primary malignances.
Where it is running
1 location listed.
- Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College - Beijing, China